Bioprosthetic Aortic Valve Replacement in Nonelderly Adults: A Systematic Review, Meta-Analysis, Microsimulation
- PMID: 30760011
- DOI: 10.1161/CIRCOUTCOMES.118.005481
Bioprosthetic Aortic Valve Replacement in Nonelderly Adults: A Systematic Review, Meta-Analysis, Microsimulation
Abstract
Background To support decision-making in aortic valve replacement in nonelderly adults, we aim to provide a comprehensive overview of reported outcome after bioprosthetic aortic valve replacement and to translate this to age-specific patient outcome estimates. Methods and Results A systematic review was conducted for papers reporting clinical outcome after aortic valve replacement with currently available bioprostheses in patients with a mean age <55 years, published between January 1, 2000, and January 9, 2016. Pooled reported event rates and time-to-event data were pooled and entered into a microsimulation model to calculate life expectancy and lifetime event risk for the ages of 25, 35, 45, and 55 years at surgery. Nineteen publications were included, encompassing a total of 2686 patients with 21 117 patient-years of follow-up (pooled mean follow-up: 7.9±4.2 years). Pooled mean age at surgery was 50.7±11.0 years. Pooled early mortality risk was 3.30% (95% CI, 2.39-4.55), late mortality rate was 2.39%/y (95% CI, 1.13-2.94), reintervention 1.82%/y (95% CI, 1.31-2.52), structural valve deterioration 1.59%/y (95% CI, 1.21-2.10), thromboembolism 0.53%/y (95% CI, 0.42-0.67), bleeding 0.22%/y (95% CI, 0.16-0.32), endocarditis 0.48%/y (95% CI, 0.37-0.62), and 20-year pooled actuarial survival was 58.7% and freedom from reintervention was 29.0%. Median time to structural valve deterioration was 17.3 years and median time to all-cause first reintervention was 16.9 years. For a 45-year-old adult, for example, this translated to a microsimulation-based estimated life expectancy of 21 years (general population: 32 years) and lifetime risk of reintervention of 78%, structural valve deterioration 71%, thromboembolism 12%, bleeding 5%, and endocarditis 9%. Conclusions Aortic valve replacement with bioprostheses in young adults is associated with high structural valve deterioration and reintervention rates and low, though not absent, hazards of thromboembolism and bleeding. Foremostly, most patients will require one or more reinterventions during their lifetime and survival is impaired in comparison with the age- and sex-matched general population. Prosthesis durability remains the main concern in nonelderly patients.
Keywords: aortic valve replacement; bioprosthesis; meta-analysis; microsimulation; nonelderly adults.
Comment in
-
Look at the Valve but Listen to the Patient.Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e005498. doi: 10.1161/CIRCOUTCOMES.119.005498. Circ Cardiovasc Qual Outcomes. 2019. PMID: 30760005 No abstract available.
Similar articles
-
The Ross Procedure: A Systematic Review, Meta-Analysis, and Microsimulation.Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e004748. doi: 10.1161/CIRCOUTCOMES.118.004748. Circ Cardiovasc Qual Outcomes. 2018. PMID: 30562065
-
Mechanical aortic valve replacement in non-elderly adults: meta-analysis and microsimulation.Eur Heart J. 2017 Dec 1;38(45):3370-3377. doi: 10.1093/eurheartj/ehx199. Eur Heart J. 2017. PMID: 29045647
-
Bioprosthetic aortic valve replacement in elderly patients: Meta-analysis and microsimulation.J Thorac Cardiovasc Surg. 2019 Jun;157(6):2189-2197.e14. doi: 10.1016/j.jtcvs.2018.10.040. Epub 2018 Oct 22. J Thorac Cardiovasc Surg. 2019. PMID: 30501946
-
Safety, efficacy, and hemodynamic performance of a stented bovine pericardial aortic valve bioprosthesis: Two-year analysis.J Thorac Cardiovasc Surg. 2020 Aug;160(2):371-381.e4. doi: 10.1016/j.jtcvs.2019.07.132. Epub 2019 Sep 9. J Thorac Cardiovasc Surg. 2020. PMID: 31590957 Clinical Trial.
-
Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age.J Thorac Cardiovasc Surg. 2014 Jan;147(1):264-9. doi: 10.1016/j.jtcvs.2012.10.032. Epub 2012 Nov 14. J Thorac Cardiovasc Surg. 2014. PMID: 23158257
Cited by
-
Narrative review of the contemporary surgical treatment of unicuspid aortic valve disease.Cardiovasc Diagn Ther. 2021 Apr;11(2):503-517. doi: 10.21037/cdt-20-814. Cardiovasc Diagn Ther. 2021. PMID: 33968629 Free PMC article. Review.
-
Five-year results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement-the ARISE Study and ARISE Registry Data.Eur J Cardiothorac Surg. 2024 Mar 29;65(4):ezae121. doi: 10.1093/ejcts/ezae121. Eur J Cardiothorac Surg. 2024. PMID: 38532304 Free PMC article. Clinical Trial.
-
Aortic Stenosis: Diagnosis, Molecular Mechanisms and Therapeutic Strategies-A Comprehensive Review.J Clin Med. 2025 Jul 12;14(14):4949. doi: 10.3390/jcm14144949. J Clin Med. 2025. PMID: 40725641 Free PMC article. Review.
-
Cardiovascular computed tomography for the detection of quadricuspid aortic valve: A case report.Radiol Case Rep. 2023 Jul 29;18(10):3544-3548. doi: 10.1016/j.radcr.2023.06.056. eCollection 2023 Oct. Radiol Case Rep. 2023. PMID: 37547798 Free PMC article.
-
Paediatric aortic valve replacement: a meta-analysis and microsimulation study.Eur Heart J. 2023 Sep 7;44(34):3231-3246. doi: 10.1093/eurheartj/ehad370. Eur Heart J. 2023. PMID: 37366156 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources